Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
64
Language
English
Published on
04/05/21
You may also be interested by these reports :
17/07/25
The reported FY2024-25 numbers fell short of our expectations due to higher-than-anticipated operating and other financial expenses. In the near ...
14/07/25
Drägerwerk’s Q2 2025 preliminary results fell short of our estimates. Net sales increased by 1.8%, with a 5% growth in the medical division ...
11/07/25
Given the numerous new product launches, high adoption of existing products, increased presence in point-of-care testing and robust balance sheet, we ...
07/07/25
Sartorius (BUY; Germany), a historically pristine business, has fallen off its perch. Following the big and expensive bet on Polyplus, Sartorius ...